Skip to main content

CASE REPORT article

Front. Med.
Sec. Pulmonary Medicine
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1406515
This article is part of the Research Topic Case Reports in Pulmonary Medicine 2024 View all 9 articles

Emerging Therapies for Transformed Small Cell Lung Cancer: Efficacy of Serplulimab and a Comprehensive Case Report

Provisionally accepted
Heng-Xu Lyu Heng-Xu Lyu 1Wen-Hua Ma Wen-Hua Ma 1Yong-Qian Zhang Yong-Qian Zhang 1Hui Jin Hui Jin 2Yu-Dong Wang Yu-Dong Wang 2*Min Zhao Min Zhao 1*
  • 1 The First hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
  • 2 Department of Medical oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China

The final, formatted version of the article will be published soon.

    This research reports a case of histological transformation from non-small cell lung cancer (NSCLC) to transformed small cell lung cancer (T-SCLC) in a patient undergoing EGFR-tyrosine kinase inhibitors (TKIs). The aggressive characteristics of the tumor diverged significantly from those commonly associated with lung adenocarcinomas, leading to further histological analysis. The subsequent histological examination confirmed the transformation to SCLC, consistent with established mechanisms of acquired resistance in NSCLC. Given the limited therapeutic options, the patient was administered a serplulimab-based immunochemotherapy regimen, achieving a progression-free survival (PFS) of 6 months post-transformation. The study underscores the potential of PD-1 inhibitors, particularly serplulimab, in the treatment landscape for T-SCLC and highlights the need for future comprehensive research.

    Keywords: Transformed Small Cell Lung Cancer (T-SCLC), Immune checkpoint inhibitors (ICIs), Immunotherapy, Non-small cell lung cancer (NSCLC), case report

    Received: 25 Mar 2024; Accepted: 09 Sep 2024.

    Copyright: © 2024 Lyu, Ma, Zhang, Jin, Wang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yu-Dong Wang, Department of Medical oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050020, Hebei Province, China
    Min Zhao, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.